Ensysce Sets Dec 14 Vote on 358.3M-Share Series C Conversion, Reverse Split and Share Increase
ENSC sits 68% above its 52-week low of $0.23.
Summary
Ensysce's definitive proxy sets a December 14, 2026 meeting to vote on converting Series C Preferred into about 358.3 million shares, a 1-for-10 to 1-for-30 reverse split, and raising authorized shares to 500 million.
Key Events · Corporate Governance and Compliance · ENSC
-
Series C Conversion Vote Set
Proposal 1 seeks approval to issue 358,292,000 common shares underlying Series C Preferred; post-conversion shares outstanding would rise from 19,456,794 to 377,748,794.
-
Reverse Split Proposed
Proposal 2 authorizes a 1-for-10 to 1-for-30 reverse split, with the Board targeting a post-split price of roughly $7.00-$11.00 to meet Nasdaq's $4.00 initial listing bid requirement.
-
Authorized Shares to Double
Proposal 3 would raise authorized common stock from 250,000,000 to 500,000,000 shares, contingent on the reverse split being implemented.
-
Delisting Risk on Non-Approval
The proxy states that if Proposal 1 fails, the company cannot convert the Series C Preferred without facing Nasdaq delisting, and must re-solicit approval every six months.
Analysis · ENSC · Life Sciences
This definitive proxy locks in the December 14, 2026 annual meeting and puts the full post-merger capital structure to a shareholder vote. The central item is Proposal 1: approving conversion of Series C Preferred into roughly 358.3 million common shares, which would take shares outstanding from 19,456,794 to 377,748,794 — the new Cy Biopharma holders and PIPE investors would control the company. Because Nasdaq has deemed the deal a change of control, the company must first satisfy Nasdaq's $4.00 initial listing bid price, so Proposal 2 authorizes a reverse split of 1-for-10 to 1-for-30 (Board targeting roughly $7-$11 post-split) and Proposal 3 doubles authorized shares to 500 million. Failure to pass Proposal 1 risks delisting. The Board may adjourn the meeting (Proposal 9) to implement the split and secure Nasdaq listing approval before the remaining votes.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENSC was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $0.23 to $2.17. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.